We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Histone deacetylase inhibitor AR-42 enhances E7-specific CD8 T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
- Authors
Lee, Sung; Huang, Zhuomin; Kang, Tae; Soong, Ruey-Shyang; Knoff, Jayne; Axenfeld, Ellen; Wang, Chenguang; Alvarez, Ronald; Chen, Ching-Shih; Hung, Chien-Fu; Wu, T.-C.
- Abstract
We have previously created a potent DNA vaccine encoding calreticulin linked to the human papillomavirus (HPV) oncogenic protein E7 (CRT/E7). While treatment with the CRT/E7 DNA vaccine generates significant tumor-specific immune responses in vaccinated mice, the potency with the DNA vaccine could potentially be improved by co-administration of a histone deacetylase inhibitor (HDACi) as HDACi has been shown to increase the expression of MHC class I and II molecules. Thus, we aimed to determine whether co-administration of a novel HDACi, AR-42, with therapeutic HPV DNA vaccines could improve the activation of HPV antigen-specific CD8 T cells, resulting in potent therapeutic antitumor effects. To do so, HPV-16 E7-expressing murine TC-1 tumor-bearing mice were treated orally with AR-42 and/or CRT/E7 DNA vaccine via gene gun. Mice were monitored for E7-specific CD8 T cell immune responses and antitumor effects. TC-1 tumor-bearing mice treated with AR-42 and CRT/E7 DNA vaccine experienced longer survival, decreased tumor growth, and enhanced E7-specific immune response compared to mice treated with AR-42 or CRT/E7 DNA vaccine alone. Additionally, treatment of TC-1 cells with AR-42 increased the surface expression of MHC class I molecules and increased the susceptibility of tumor cells to the cytotoxicity of E7-specific T cells. This study indicates the ability of AR-42 to significantly enhance the potency of the CRT/E7 DNA vaccine by improving tumor-specific immune responses and antitumor effects. Both AR-42 and CRT/E7 DNA vaccines have been used in independent clinical trials; the current study serves as foundation for future clinical trials combining both treatments in cervical cancer therapy. Key message:
- Subjects
HISTONE deacetylase inhibitors; CD8 antigen; T cells; PAPILLOMAVIRUSES; HUMAN papillomavirus vaccines; ONCOGENIC proteins; PHYSIOLOGY
- Publication
Journal of Molecular Medicine, 2013, Vol 91, Issue 10, p1221
- ISSN
0946-2716
- Publication type
Article
- DOI
10.1007/s00109-013-1054-9